Industry Supported Sessions Programs

Industry Supported Sessions Programs

Friday, March 16, 2018

 

09:15 – 11:15

Sala 500

INTERCEPTING ALZHEIMER'S DISEASE
COMPLEX PROBLEM, COMPLETE SOLUTION

Symposium Organized by:

ROCHE

CHAIR: Jeffrey Cummings, USA

09:15                A MULTIFACETED DISEASE: WHY WE NEED TO TACKLE AD FROM ALL ANGLES
  Jeffrey Cummings, USA

09:35                ACTING EARLY IN AD: GIVING PATIENTS THE BEST CHANCE
Jean Georges, Luxembourg

09:55                THE BIOMARKER TOOLBOX: CHANGING CLINICAL PRACTICE NOW AND FOR THE FUTURE
Kaj Blennow, Sweden

10:15                LEADING THE FIGHT: AN EXPLORATION OF MULTIPLE AD TARGETS AND BETTER CLINICAL TRIALS
Rachelle Doody, Switzerland

10:35                THE FUTURE IN COLLABORATION: WHAT CAN BE DONE FURTHER FOR PATIENTS WITH EARLY ONSET/HIGHEST AD RISK?
Randall Bateman, USA

10:55                PANEL Q&A
All Faculty

11:10                SUMMARY AND CLOSE

Jeffrey Cummings, USA

 

11:45 – 13:25

Sala 500

THE EARLY DIAGNOSIS OF ALZHEIMER'S DISEASE: IT'S ABOUT TIME

Symposium Organized by:

BIOGEN

CHAIR: José Luis Molinuevo, SPAIN

11:45                 WELCOME AND INTRODUCTION
 José Luis Molinuevo, Spain

11:50                CASE STUDY PART 1: PATIENT PRESENTATION – HISTORIC SIGNS AND SYMPTOMS OF THE EARLY STAGES OF ALZHEIMER'S DISEASE
José Luis Molinuevo, Spain

12:00                NEUROPSYCHOLOGICAL TOOLS: ASSESSMENT OF THE APPROPRIATE COGNITIVE DOMAINS IN THE DIAGNOSIS OF THE EARLY STAGES OF ALZHEIMER'S DISEASE
James Galvin, USA

12:10                CASE STUDY PART 2: NEUROPSYCHOLOGICAL RESULTS FOR A PATIENT IN THE EARLY STAGES OF ALZHEIMER'S DISEASE
José Luis Molinuevo, Spain             

12:30                CASE STUDY PART 3: REVISED BIOMARKER ASSESSMENT – EVALUATION OF DISCORDANT BIOMARKERS IN THE DIAGNOSIS OF THE EARLY STAGES OF ALZHEIMER'S DISEASE
José Luis Molinuevo, Spain             

12:40                BIOMARKERS IN THE EVALUATION OF THE EARLY STAGES OF ALZHEIMER'S DISEASE: A COMPARISON OF AMYLOID PET AND CSF
Lucilla Parnetti, Italy and  Jonathan Schott, UK

13:00                CASE STUDY PART 4: BACK TO THE EVIDENCE – MAKING A DIAGNOSIS
José Luis Molinuevo, Spain                                              

13:05                PATIENT MANAGEMENT DURING THE EARLY STAGES OF ALZHEIMER'S DISEASE
Wiesje van der Flier, The Netherlands

13:20                SUMMARY AND CLOSE
José Luis Molinuevo, Spain

 Saturday, March 17, 2018

 

08:45 – 10:45

Sala 500

PARKINSON'S DISEASE PERSONALIZED MEDICINE: GBA AND LRRK2 

Symposium Organized by:

SANOFI

CHAIRS: Laurent Pradier, France and Tanya Fischer, USA

08:45                GENETICS OF PD: THE EXAMPLE OF GBA AND LRRK2
 Stefano Goldwurm, Italy

09:06                THE ROLE OF GBA IN PARKINSON'S DISEASE
Pablo Sardi, USA

09:31                POTENTIAL FUTURE APPROACHES FOR PARKINSON'S DISEASE TARGETING THE LYSOSOMES
Nir Giladi, Israel

09:56                CAN BIOMARKERS INFORM DESIGN OF DISEASE MODIFICATION TRIALS? PPMI DATA MINING
Tatanya Simuni, USA

10:21                LRRK2 INHIBITORS FOR TREATING LRRK2-LINKED PD
Andy West, USA

 

11:15 – 12:55

Sala 500

ALZHEIMER'S DISEASE MODIFYING THERAPIES: IS IT TIME TO MOVE BEYOND THE AMYLOID CASCADE?

Symposium Organized by:

ASTRAZENECA AND ELI LILLY AND COMPANY

CHAIR: Teresa Gomez-Isla, USA 

11:15                WELCOME AND INTRODUCTIONS
Teresa Gomez-Isla, USA

11:20                THE AMYLOID CASCADE: MUST DISEASE MODIFICATION BEGIN THERE?Teresa Gomez-Isla, USA

11:45                POTENTIAL DOWNSTREAM EFFECTS OF AMYLOID TARGETED THERAPIES
Luc Buee, France

12:10                ALZHEIMER'S DISEASE TREATMENT STRATEGIES AND POTENTIAL BENEFITS & RISKS
Clive Ballard, UK

12:35                PANEL DISCUSSION, QUESTIONS & ANSWERS AND CLOSING REMARKS
All

 

Keep Me Updated